Rarecells, Inc. has made an exciting announcement about a major breakthrough in the detection of Circulating Giant Cancer Cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS).
In collaboration with Dr. Azra Raza from Columbia University Irving Medical Center, Rarecells has conducted groundbreaking research that has revealed the presence of CGCCs in MDS patients for the first time ever. This discovery is particularly significant as MDS patients are at risk of developing acute myeloid leukemia (AML).
The results of this collaborative study have been published in the Medical Oncology journal under the title "Circulating cancer giant cells with unique characteristics frequently found in patients with myelodysplastic syndromes (MDS)". The research utilized Rarecells' highly sensitive proprietary ISET® technology to isolate and identify these circulating Giant Cells.
Myel